SH2 domain-containing protein 5 (SH2D5)

SH2 domain-containing protein 5 (SH2D5) is an adaptor-like intracellular protein characterized by the presence of an N-terminal phosphotyrosine-binding (PTB) domain and a C-terminal SH2-like domain[2][4][6]. It is encoded on human chromosome 1 and is primarily expressed at high levels in the brain, particularly in neurons of the cerebral cortex, hippocampal formation, amygdala, and basal ganglia, as well as in the testis[4]. SH2D5 regulates synaptic plasticity, partly via interaction with the breakpoint cluster region (BCR) protein and subsequent modulation of Rac1-GTP, influencing cytoskeletal and signaling dynamics[2][6]. SH2D5 expression is elevated in cancers such as hepatitis B virus-induced hepatocellular carcinoma (HBV-HCC), where high expression correlates with poor prognosis and advanced clinical features[6]. Genome-wide association analyses have implicated SH2D5 in central nervous system disorders, including a potential role in Alzheimer's disease and headache disorders via its epigenetic regulation[4]. As of now, there are no known therapeutic drugs targeting SH2D5, and it is not considered a canonical therapeutic target such as a receptor, enzyme, or transporter. However, it has significance as a biomarker for disease progression and prognosis in oncology and neurological research[2][4][6].

Other names

SH2D5SH2 domain containing 5SH2 domain-containing protein 5